Aflac Incorporated (AFL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there are positive developments, such as strong sales performance in certain areas and AI integration, there are also concerns like negative earned premium growth in Japan and unclear management responses. The overall sentiment seems balanced, with no strong catalysts to drive a significant stock price movement either way.
Key Financial Performance
Net earnings per diluted share (Q4 2025) $2.64, with adjusted earnings per diluted share at $1.57. Adjusted earnings per diluted share increased 0.6% year-over-year. The increase was attributed to remeasurement gains on reserves totaling $36 million, which reduced benefits, and a solid adjusted ROE of 11.7% (14.5% excluding foreign currency remeasurement).
Net earnings per diluted share (2025) $6.82, with adjusted earnings per diluted share at $7.49. The reasons for the strong performance were not explicitly detailed but reflect overall solid financial results.
Aflac Japan sales (Q4 2025) Increased by 15.7% year-over-year. This was driven by a 35.6% sales increase in the Miraito cancer insurance product launched in March and positive reception of the Anshin Palette medical product introduced in December.
Aflac Japan sales (2025) Increased by 16% year-over-year. The growth was attributed to the success of new products like Miraito and Anshin Palette, as well as a focus on third-sector protection and younger customers.
Premium persistency (Aflac Japan, 2025) Remained strong at 93.1%, despite lapses tied to the launch of Miraito. Persistency was supported by the value customers place on Aflac's products.
Net earned premiums (Aflac U.S., 2025) Increased by 2.9% year-over-year. This growth was driven by strong underwriting discipline and premium persistency of 79.2%.
New sales (Aflac U.S., 2025) Generated nearly $1.6 billion, with over one-third of the sales occurring in Q4. The reasons for this growth were not explicitly detailed.
Net earned premiums (Aflac Japan, Q4 2025) Declined by 1.9% in yen terms. Underlying earned premiums (excluding deferred profit liability, paid-up policies, and reinsurance) declined by 1.2%. The decline reflects long-term premium trends.
Total benefit ratio (Aflac Japan, Q4 2025) Came in at 65%, down 150 basis points year-over-year. The decrease was due to reserve remeasurement gains, which had a favorable impact of approximately 110 basis points.
Expense ratio (Aflac Japan, Q4 2025) Increased to 22%, up 120 basis points year-over-year. The increase was driven by sales promotion expenses associated with higher sales.
Adjusted net investment income (Aflac Japan, Q4 2025) Decreased by 3.9% in yen terms. This was primarily due to lower floating rate income on the U.S. dollar book and lower variable investment income, partially offset by higher U.S. dollar fixed income due to higher volume.
Pretax margin (Aflac Japan, Q4 2025) 31.3%, down 30 basis points year-over-year. The decline was attributed to the factors affecting net earned premiums and investment income.
Net earned premiums (Aflac U.S., Q4 2025) Increased by 4% year-over-year. The growth was supported by strong premium persistency of 79.2%.
Total benefit ratio (Aflac U.S., Q4 2025) 48.6%, up 230 basis points year-over-year. The increase was driven by prior year endorsements, higher claims activity on the individual voluntary block, and a higher benefit ratio on group life and disability.
Expense ratio (Aflac U.S., Q4 2025) 40.4%, up 10 basis points year-over-year. The increase was primarily driven by timing of spend from previous quarters and growth initiatives like group life and disability, network dental and vision, and direct-to-consumer.
Adjusted net investment income (Aflac U.S., Q4 2025) Decreased by 2.8% year-over-year. This was primarily due to a reduction in floating rate assets and corresponding rates.
Pretax margin (Aflac U.S., Q4 2025) 17.4%, down 230 basis points year-over-year. The decline was attributed to higher claims activity and increased expenses.
Capital deployment (2025) Aflac deployed $3.5 billion to repurchase 33 million shares and paid $1.2 billion in dividends. This resulted in a total of $4.8 billion returned to shareholders. The strong capital deployment reflects the company's financial strength and commitment to shareholder returns.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Miraito Cancer Insurance: Launched in March, it drove a 35.6% sales increase in Japan for Q4 2025.
Anshin Palette Medical Product: Introduced in late December, received positive reception.
Tsumitasu First Sector Product: Repriced in September, aimed at younger customers.
Japan Market Expansion: Sales increased by 15.7% in Q4 2025 and 16% for the year, supported by broadened distribution channels including agencies, alliance partners, and banks.
U.S. Market Expansion: Generated nearly $1.6 billion in new sales in 2025, with over one-third in Q4.
Premium Persistency in Japan: Maintained strong persistency at 93.1% for 2025 despite lapses tied to new product launches.
Premium Persistency in U.S.: Maintained strong persistency at 79.2% for 2025.
Expense Management in U.S.: Continued prudent expense management while maintaining a strong pretax margin.
Capital Deployment: Deployed $3.5 billion to repurchase 33 million shares and paid $1.2 billion in dividends in 2025.
Dividend Increase: Board approved a 5.2% increase in the first quarter 2026 dividend.
Liquidity and Capital Flexibility: Enhanced by $2 billion through off-balance sheet precapitalized trusts.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Premium Persistency in Japan: Premium persistency in Japan reflected lapses tied to the launch of the Miraito cancer insurance product. While persistency remains strong at 93.1%, maintaining this level is vital to offset the impact of reinsurance and policies reaching paid-up status in the future.
Expense Ratio in Japan: The expense ratio in Japan increased by 120 basis points year-over-year, driven primarily by sales promotion expenses associated with higher sales.
Premium Persistency in the U.S.: Premium persistency in the U.S. declined slightly by 10 basis points year-over-year to 79.2%, which could impact long-term premium growth.
Benefit Ratio in the U.S.: The total benefit ratio in the U.S. increased by 230 basis points year-over-year, driven by prior year endorsements, higher claims activity on the individual voluntary block, and a higher benefit ratio on group life and disability.
Investment Income: Adjusted net investment income in both Japan and the U.S. declined due to lower floating rate income and variable investment income, which could impact overall profitability.
Capital Deployment: While the company deployed significant capital for share repurchases and dividends, the sustainability of such high levels of capital deployment could be a challenge if market conditions or profitability deteriorate.
Regulatory and Market Risks: The company faces regulatory and market risks, including sensitivity to yen-dollar exchange rates and yen interest rates, which could impact leverage ratios and financial stability.
Scaling New Business Lines in the U.S.: The expense ratio in the U.S. increased due to growth initiatives in group life and disability, network dental and vision, and direct-to-consumer businesses. These initiatives are still scaling and could pressure margins in the short term.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Aflac Japan's 2026 Outlook: Underlying earned premiums are expected to decline by 1% to 2%. The expense ratio is projected to be in the range of 20% to 23%. The benefit ratio is anticipated to be between 60% and 63%. The pretax profit margin is expected to range from 33% to 36%.
Aflac U.S. 2026 Outlook: Net earned premium growth is expected to be at the lower end of the 3% to 6% range. The benefit ratio is projected to be between 48% and 52%. The expense ratio is anticipated to be in the range of 36% to 39%. The pretax profit margin is expected to range from 17% to 20%.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Increase: The Board decided to increase the first quarter of 2026 dividend by 5.2%.
Dividend Payments in 2025: Aflac paid dividends totaling $1.2 billion in 2025.
Dividend Growth Record: Aflac has achieved 43 consecutive years of dividend increases.
Share Repurchase in 2025: Aflac repurchased 33 million shares of its stock, deploying a record $3.5 billion.
Total Shareholder Return in 2025: Combining share repurchase and dividends, Aflac delivered nearly $4.8 billion back to shareholders in 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Do you expect higher levels of surrender in Japan due to rising super long yields?
A:Max Broden stated that while significant moves up in the yen yield curve have been observed, the company has not yet experienced increased demand or lapsation of in-force policies. However, they are closely monitoring and preparing for such scenarios.
Q:Is there any change in thinking around M&A or capital deployment once ESR is printed in 2026?
A:Max Broden explained that the company has significant capital flexibility and evaluates M&A through operational, strategic, and financial lenses. While they have capital available for potential M&A, finding suitable targets in their niche markets in the U.S. and Japan is challenging. Currently, they are satisfied with their existing businesses.
Q:Can you explain the lower benefit ratio embedded in the guidance for Japan?
A:Max Broden outlined three factors: (1) A permanent reduction in the net premium ratio by 130 basis points due to updated actuarial assumptions in Q3 2025. (2) Lapse and reissue activity from new product introductions, which releases reserves and lowers the benefit ratio. (3) The runoff of older high-benefit-ratio life insurance savings policies sold between 2010-2016, which reduces the overall benefit ratio.
Q:What is the total addressable market for new products like Tsumitasu and Anshin Palette in Japan?
A:Koichiro Yoshizumi explained that Tsumitasu targets individual customers seeking yen-denominated level payment products, including young and middle-aged generations. It has also gained popularity among affluent middle-aged to older customers. The company can adjust premium rates based on market conditions. Daniel Amos added that Miraito, a new cancer policy, performed exceptionally well, and sales growth is expected in medical products and Tsumitasu.
Q:What drove the growth in U.S. supplemental health sales while disability sales were down?
A:Virgil Miller reported that overall U.S. sales reached $1.6 billion, with life absence and disability making up 20% of the total. Supplemental health sales grew due to strong performance in network dental (up 48.8%) and direct-to-consumer platforms (up 10.5%). Disability sales were down, but overall performance was balanced with strong persistency at 79.2%.
Q:What caused the decline in the uplift from the USP in ESR?
A:Max Broden attributed the decline in the uplift from the USP to higher yen interest rates, which reduce the impact of the USP.
Q:Are statutory or economic margins in Japan improving despite changes in the benefit ratio?
A:Max Broden explained that while the U.S. GAAP benefit ratio is expected to decline by 130 basis points in 2026, this impact will not occur on an FSA earnings basis. About one-third of the decline is due to the net premium ratio, while the other two-thirds will affect both U.S. GAAP and FSA earnings.
Q:What is the outlook for the Bermuda entity and its use for reinsurance?
A:Max Broden stated that 6% of Aflac Japan's balance sheet has been ceded to Bermuda, with a midterm target of 10%. This is not an absolute limit, and the company will evaluate higher internal limits over time. Significant capacity remains for ceding business between Japan and Bermuda.
Q:Why is the U.S. benefit ratio guidance higher than recent trends?
A:Max Broden explained that the U.S. benefit ratio is increasing due to higher benefit ratios on cancer and accident products, as well as a mix shift towards group life, disability, and dental products, which carry higher benefit ratios.
Q:What is the impact of a K-shaped economy on consumer behavior and agent recruiting?
A:Virgil Miller noted that despite economic volatility, there was no material impact on Aflac's business. Career recruiting increased, with higher conversion rates and productivity. The company also saw increased activity in its direct-to-consumer channel, particularly among those affected by ACA changes.
Q:What is the growth outlook for group versus non-group sales in the U.S.?
A:Virgil Miller reported strong growth in group sales, with network dental up 48.8%, life absence and disability up 11.3%, and traditional group benefits up 11.7%. However, traditional voluntary benefits have been flat to negative, which offsets the growth in group sales.
Q:Why is Japan's earned premium growth still negative despite strong sales?
A:Max Broden explained that Japan's high persistency means new sales are relatively small compared to the large in-force block. While sales are closing the gap with lapses, earned premium growth is expected to turn positive within a reasonable future, but lapses will still exceed sales in 2026.
Q:What are the non-core impacts on Japan's premium growth guidance?
A:Max Broden clarified that the guidance excludes impacts from deferred profit liability, paid-up policies, and reinsurance. The delta between underlying and actual premiums is expected to be smaller in 2026 due to a declining balance of paid-up impacts.
Q:How is Aflac leveraging artificial intelligence (AI) in its operations?
A:Virgil Miller stated that AI is being used to automate routine processes, assist claims adjudicators, and enhance enrollment processes. In Japan, AI is being explored for product innovation and distribution. The focus is on using AI to assist rather than replace human roles.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the question about the total addressable market for new products like Tsumitasu and Anshin Palette in Japan. While they provided some context about the target audience and market conditions, they did not offer specific data or detailed projections. Additionally, the response to the question about the Bermuda entity's reinsurance capacity lacked clarity on whether the 10% target could be revised higher in the near term.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALM exposure
Aflac Conference
Aflac founding
Aflac partner
Aflac product
Blood Disorder
Conference Instructions
Corporate loss
Disorder Center
ESR effect
ESR sensitivity
FAB strength
Inc liquidity
International President
Investments security
JPY
Miraito
President Capital
QA
USP
analyst
anniversary
distribution channel
estimate
flexibility
group life
income dollar
increase sale
lapse
liquidity balance
milestone
net premium
period
persistency net
pocket
product introduction
range
record share
uptick
valuation allowance
yen interest
AFL Transcript
Aflac Incorporated (AFL) Presents at Morgan Stanley US Financials Conference 2026 Transcript
Neutral6-9
Aflac Incorporated (AFL) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call summary shows a modest positive financial performance with revenue and net earnings growth, but lacks discussion on strategic initiatives and operational updates. Regulatory, market, and economic risks are highlighted, which could offset financial gains. The absence of strategic discussions and potential regulatory hurdles suggest caution. Overall, the financial performance is positive, but uncertainties and risks balance the sentiment, leading to a neutral outlook.
Aflac Incorporated (AFL) Presents at UBS Financial Services Conference 2026 Transcript
Neutral2-11
Aflac Incorporated (AFL) Q4 2025 Earnings Call Transcript
Unknown2-5
The earnings call presents a mixed picture. While there are positive developments, such as strong sales performance in certain areas and AI integration, there are also concerns like negative earned premium growth in Japan and unclear management responses. The overall sentiment seems balanced, with no strong catalysts to drive a significant stock price movement either way.
AFL Slides
AFL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
